On June 7, 2022 CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, reported that its Chief Executive Officer, Dr. Joseph Sarret, will participate at two upcoming conferences (Press release, CohBar, JUN 7, 2022, View Source [SID1234615711]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BIO International Convention – June 13-16, 2022
June 14th at 5:00 pm PT, San Diego, CA
The presentation may be accessed via webcast at the scheduled time for registered attendees only.
4th Annual Longevity Therapeutics Summit – June 28-30, 2022
June 30th at 10:30 am PT, San Francisco, CA
Dr. Sarret will be participating on a panel titled "Investing in Longevity", along with leaders from venture capital, large pharmaceuticals, and innovative biotechs to discuss how to navigate investments and funding in this lucrative field. Joining Dr. Sarret on this panel is Anastasiya Giarletta, Principal at R42 Group, Kate Batz, Director at Deep Knowledge Investors, and Karl Pfleger, Founder at Agingbiotech.info.